News / Taiwan / cnyes
Evercyte August Revenue Hits Yearly High of NT$110 Million
Health Technology · Biotechnology · cnyes · 2026-09-01
6712
Taiwan-based cell therapy firm Evercyte reported an August revenue of NT$110 million, marking a year-to-date high driven by robust growth in CDMO and cell services.
What Happened
Revenue Performance: Evercyte (6712) announced August revenue of NT$110 million, representing a 10.47% monthly increase and a 21.1% year-on-year growth. This achievement marks the company's highest monthly revenue for the year, with cumulative revenue for the first eight months reaching NT$669 million.
Market Trends: The company highlighted the recent clinical success of mRNA-based cancer treatments, which validates the commercial potential of mRNA technology beyond infectious diseases. Evercyte is leveraging these industry trends to enhance its own technological capabilities.
R&D Strategy: Evercyte's lead pipeline candidate, CAR001, utilizes a differentiated strategy focused on off-the-shelf, standardized cell therapy. The project has successfully completed Phase 1 clinical trials and is currently advancing through Phase 2a to gather critical safety and efficacy data.
Future Outlook: Moving forward, the company plans to maintain its momentum by integrating CDMO services with its proprietary drug pipelines, including EXO001 and dEV001. Management remains committed to advancing its AI and exosome-based manufacturing platforms to capture emerging market opportunities.